Nonpeptide mimic of bradykinin with long-acting properties at the bradykinin B2 receptor

Molecular Pharmacology

Volumn 52, Issue 1, 1997, Pages 16-20

  Aramori, Ichiro ^a   Zenkoh, Junko ^a   Morikawa, Noriyuki ^a   Asano, Masayuki ^a   Hatori, Chie ^a   Sawai, Hiroe ^a   Kayakiri, Hiroshi ^a   Satoh, Shigeki ^a   Inoue, Takayuki ^a   Abe, Yoshito ^a   Sawada, Yuki ^a   Mizutani, Tsuyoshi ^a   Inamura, Noriaki ^a   Nakahara, Kunio ^a   Kojo, Hitoshi ^a   Oku, Teruo ^a   Notsu, Yoshitada ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 [2,6 DICHLORO 3 (N 4 (N METHYLCARBAMOYL)CINNAMIDOACETYL) N METHYLAMINO]BENZYLOXY] 2 METHYL 4 (2 PYRIDYLMETHOXY)QUINOLINE; 8 [2,6 DICHLORO 3 [N [4 (N METHYLCARBAMOYL)CINNAMAMIDOACETYL] N METHYLAMINO]BENZYLOXY] 2 METHYL 4 (2 PYRIDYLMETHOXY)QUINOLINE; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ RECEPTOR AGONIST; ICATIBANT; LONG ACTING DRUG; PHOSPHATIDYLINOSITOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

EID: 0030811668     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.1.16     Document Type: Article

References (29)

1. Regoli, D., and J. Barabé. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32:1-46 (1980).
2. Proud, D., and A. P. Kaplan. Kinin formation: mechanisms and role in inflammatory disorders. Annu. Rev. Immunol. 6:49-83 (1988).
3. Dray, A., and M. Parkins. Bradykinin and inflammatory pain. Trends Neurosci. 16:99-104 (1993).
4. 2 receptor characterization. Trends Pharmacol. Sci. 11:156-161 (1991).
5. 2 bradykinin receptor. Proc. Natl. Acad. Sci. USA 88:7724-7728 (1991).
6. Hess, J. F., J. A. Borkowski, G. S. Young, C. D. Strader, and R. W. Ransom. Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem. Biophys. Res. Commun. 184:260-268 (1992).
7. 1 bradykinin receptor. J. Biol. Chem. 269:21583-21586 (1994).
8. Aramori, I., J. Zenkoh, N. Morikawa, N. O'Donnell, M. Asano, K. Nakamura, M. Iwami, H. Kojo, and Y. Notsu. Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657. Mol. Pharmacol. 51:171-176 (1997).
9. 2 receptor antagonist, FR173657. Br. J. Pharmacol. 120: 617-624 (1997).
10. 2 receptor antagonist. Proc. Natl. Acad. Sci. USA 91:4693-4697 (1994).
11. Hock, F. J., K. Wirth, U. Albus, W. Linz, H. J. Gerhards, G. Wiemer, St. Henke, G. Breipohl, W. König, J. Knolle, and B. A. Schölkens. Hoe140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br. J. Pharmacol. 102:769-773 (1991).
12. Berridge, M. J., R. M. C., Dawson, C. P. Downes, J. P. Heslop, and R. F. Irvine. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem. J. 212: 473-482 (1983).
13. Aramori, I., and S. Nakanishi. Coupling of two endothelin receptor subtypes to differing signal transduction in transfected Chinese hamster ovary cells. J. Biol. Chem. 267:12468-12474 (1992).
14. Feldberg, W., and G. P. Lewis. The action of peptides on the adrenal medulla release of adrenaline by bradykinin and angiotensin. J. Physiol. 171:98-108 (1964).
15. Bjørnstad-Østenson, A., and T. Berg. The role of nitric oxide, adrenergic activation and kinin-degradation in blood pressure homeostasis following an acute kinin-induced hypotension. Br. J. Pharmacol. 113:1567-1573 (1994).
16. Wirth, K., F. J. Hock, U. Albus, W. Linz, H. G. Alpermann, H. Anagnostopoulos, St. Henke, G. Breipohl, W. König, J. Knolle, and B. A. Schölkens. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol. 102:774-777 (1991).
17. Gilman, A. G. G proteins. Transducers of receptor-generated signals. Annu. Rev. Biochem. 56:615-649 (1987).
18. Levitzki, A. From epinephrine to cyclic AMP. Science (Washington D. C.) 241:800-806 (1988).
19. De Lean, A., J. M. Stadel, and R. J. Lefkowitz. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J. Biol. Chem. 255:7108-7117 (1980).
20. Moore, G. J., J. R. Smith, B. W. Baylis, and J. M. Matsoukas. Design and pharmacology of peptide mimetics. Adv. Pharmacol. 33:91-141 (1995).
21. Hunter, J. C., G. E. Leighton, K. G. Meecham, S. J. Boyle, D. C. Horwell, D. C. Rees, and J. Hughes. CI-997, a novel and selective agonist for the κ-opioid receptor. Br. J. Pharmacol 101:183-189 (1990).
22. 1 receptor. J. Biol. Chem. 270:1493-1496 (1995).
23. Aquino, C. J., D. R. Armour, J. M. Berman, L. S. Birkemo, R. A. E. Carr, D. K. Croom, M. Dezube, R. W. Dougherty, Jr., G. N. Ervin, M. K. Grizzle, J. E. Head, G. C. Hirst, M. K. James, M. F. Johnson, L. J. Miller, K. L. Queen, T. J. Rimele, D. N. Smith, and E. E. Sugg. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger." J. Med. Chem. 39:562-569 (1996).
24. 1 ligands: susceptibility to receptor mutations. Mol. Pharmacol. 51:301-311 (1997).
25. Majima, M., and M. Katori. Approaches to the development of novel antihypertensive drugs: crucial role of the renal kallikrein-kinin system. Trends Pharmacol. Sci. 16:239-246 (1995).
26. Uehara, Y., N. Hirakawa, Y. Kawabata, T. Suzuki, N. Ohshima, K. Oka, T. Ikeda, A. Goto, T. Toyo-oka, K. Kizuki, and M. Omata. Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension (Dallas) 24:770-778 (1994).
27. Goto, M., Y. Liu, X.-M. Yang, J. L. Ardell, M. V. Cohen, and J. M. Downey. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 77:611-621 (1995).
28. Schill, W.-B., and W. Miska. Possible effects of the kallikrein-kinin system on male reproductive functions. Andrologia 24:69-75 (1992).
29. Inamura, T., T. Nomura, R. T. Bartus, and K. L. Black. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J. Neurosurg. 81:752-758 (1994).